Pilot Study of Hyperfractionated Dosing of Lutetium‐177–Labeled Antiprostate‐Specific Membrane Antigen Monoclonal Antibody J591 ((177)Lu‐J591) for Metastatic Castration‐Resistant Prostate Cancer

LESSONS LEARNED: Hyperfractionation of lutetium‐177 ((177)Lu)‐J591 for patients with metastatic castration‐resistant prostate cancer did not appear to have any additional advantage over the single dose (177)Lu‐J591 or fractionated two‐dose (177)Lu‐J591 therapy. Definite conclusions were challenging...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Niaz, Muhammad Junaid, Batra, Jaspreet S., Walsh, Ryan D., Ramirez‐Fort, Marigdalia K., Vallabhajosula, Shankar, Jhanwar, Yuliya S., Molina, Ana M., Nanus, David M., Osborne, Joseph R., Bander, Neil H., Tagawa, Scott T.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2020
Témata:
Clinical Trial Results
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288642/
https://ncbi.nlm.nih.gov/pubmed/31999003
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0028
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky